23.37

1.81% -0.43

After Hours: 22.84 -0.53 -2.27%

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $23.37, with a volume of 967.34K. It is down -1.81% in the last 24 hours and up +21.34% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Previous Close:

$23.80

Open:

$23.76

24h Volume:

967.34K

Relative Volume:

1.07

Market Cap:

$2.57B

Revenue:

$14.09M

Net Income/Loss:

$-176.94M

P/E Ratio:

-10.87

EPS:

-2.15

Net Cash Flow:

$-141.24M

1W Performance:

+15.29%

1M Performance:

+21.34%

6M Performance:

+41.89%

1Y Performance:

+11.44%

1-Day Range:

$22.58

$23.86

1-Week Range:

$21.00

$24.23

52-Week Range:

$15.19

$27.29

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1173)

Industry

Biotechnology (680)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	23.37	2.57B	14.09M	-176.94M	-141.24M	-2.15
VRTX Vertex Pharmaceuticals Inc	500.01	128.40B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	744.83	81.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	571.00	34.69B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	233.07	30.17B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	242.66	26.02B	3.32B	-860.46M	-1.04B	-8.32

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

Mar 10, 2025

A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News

Mar 10, 2025

Mar 06, 2025

Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com South Africa

Mar 06, 2025

Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com

Mar 06, 2025

Mar 05, 2025

New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com Australia

Mar 05, 2025

New Amsterdam Pharma chief accounting officer sells $3.06 million in shares By Investing.com - Investing.com South Africa

Mar 05, 2025

Mar 03, 2025

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha

Feb 28, 2025

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution (NASDAQ:NAMS) - Seeking Alpha

Feb 28, 2025

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

Feb 28, 2025

NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress - TipRanks

Feb 28, 2025

Feb 27, 2025

7 Analysts Have This To Say About NewAmsterdam Pharma - Benzinga

Feb 27, 2025

Scotiabank raises NewAmsterdam Pharma target to $52 - Investing.com India

Feb 27, 2025

Scotiabank raises NewAmsterdam Pharma target to $52 By Investing.com - Investing.com South Africa

Feb 27, 2025

Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence - TipRanks

Feb 27, 2025

Feb 26, 2025

NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises -February 26, 2025 at 08:27 am EST - Marketscreener.com

Feb 26, 2025

Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M - Marketscreener.com

Feb 26, 2025

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Feb 26, 2025

NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView

Feb 26, 2025

Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction - StockTitan

Feb 26, 2025

Feb 25, 2025

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - The Manila Times

Feb 25, 2025

Feb 24, 2025